First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.

Abstract

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients… (More)
DOI: 10.1002/pbc.26461

Topics

Cite this paper

@article{Creutzig2017FirstEO, title={First experience of the AML-Berlin-Frankfurt-M{\"u}nster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.}, author={Ursula Creutzig and Michael Dworzak and Konrad Bochennek and Joerg Faber and Christian Flotho and Norbert Graf and Udo Kontny and Claudia Rossig and Irene Schmid and Arend von Stackelberg and Jans-Enno Mueller and Christine von Neuhoff and Dirk Reinhardt and Nils von Neuhoff}, journal={Pediatric blood & cancer}, year={2017}, volume={64 8} }